Nomura Securities: Nomura raises Samsung Biologics target stock price by 67%, citing strong growth potential

Nomura Securities has upgraded Samsung Biologics to a "Buy" rating with a new target stock price of 1,400,000 won ($964.4), reflecting a 66.6 percent increase from the previous buy rating of 840,000 won."Samsung Biologics stands to benefit from rising global demand for outsourced pharmaceutical prod